NCT01094834已完成1 期
A Multiple Dose Study To Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP05195 in Healthy Adult Subjects
Daewoong Pharmaceutical Co. LTD.0 个研究点目标入组 40 人开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 主要终点
- Assessment of safety & tolerability: adverse events, vital signs, 12-Lead ECG, laboratory safety variables and physical examination
研究概览
简要总结
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple administered DWP05195 in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male subjects aged 20 to 45 years
- •The subject has a Body weight ≥50 kg and <90 kg and Body Mass Index(BMI) ≥19.0 kg/m2 and < 27.0 kg/m
- •A subject who provided written informed consent to participate in this study and cooperative with regard to compliance with study related constraints
- •A Subject who was judged to be healthy by the investigator to participate in this study based on screening results (according to standard reference index updated recently)
排除标准
- •A subject with sign or symptoms or previously diagnosed disease of respiratory, cardiovascular, endocrinology, liver, kidney, gastrointestinal, hematology, neurology and psychology function or other significant diseases and history or suspicion of current drug abuse and alcohol abuse
- •A subject who had any allergic history to any drug (prescription drug or OTC medication etc.)
- •A subject who had received treatment with below listed drug within specified period prior to the first dose of study medication
- •Within last 1 month : drug or food known CYP1A2 inducer or inhibitor
- •Within 2 weeks : Prescribed or herbal or Non-prescribed medicine
- •Within 3 days : Consumption of grapefruit juice/grapefruit containing products or orange juice/orange containing products, garlic extracted functional foods
- •Within 3 days : Consumption of alcohol or caffeine
- •A subject who had participated in any other clinical study within the last 12 weeks
- •A subject from whom over 400mL of blood was sampled(whole blood or plasma donation, etc.) within last 12 weeks
- •A Subject with the known evidence of the following infections or drug abuse
- •HIV, HBs, HCV
- •cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine
- •Smoker or smoking cessation within 1 month or ex-smoker with positive results by cotinine test
- •AST or ALT greater than 1.5 times the upper limit of reference range or QTc > 430 msec base on screening results
- •Blood pressure : SBP≥140mmHg, DBP≤85mmHg
- •A subject judged ineligible by the investigator to participate in this study for other reason containing clinical laboratory tests
研究组 & 干预措施
DWP05195
Experimental
干预措施: DWP05195 (Drug)
结局指标
主要结局
Assessment of safety & tolerability: adverse events, vital signs, 12-Lead ECG, laboratory safety variables and physical examination
时间窗: 17 days after drug administration
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)Hepatitis CNCT00998985Merck Sharp & Dohme LLC91
已完成
1 期
A Multiple Dose Study of MK-3614 (MK-3614-002)HypertensionNCT01033643Merck Sharp & Dohme LLC30
已完成
1 期
Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male VolunteersHealthyNCT02331277Boehringer Ingelheim12
已完成
1 期
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).Diabetes Mellitus, Non-Insulin-DependentNCT00754130Merck Sharp & Dohme LLC16
已完成
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate AsthmaAsthmaNCT01370317Merck Sharp & Dohme LLC27